A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Dabrafenib, Pembrolizumab in melanoma and non-small-cell lung cancer, run by Immuneering Corporation, active and no longer recruiting.
Overview
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05585320 by Immuneering Corporation, with 209 participants enrolled, started 2022-10-31 and due to reach its primary completion in 2026-06. Interventions recorded: IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E). Conditions listed: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAn Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Shares Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Paclitaxel / nab-paclitaxel, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Paclitaxel / nab-paclitaxel, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s
Shares Paclitaxel / nab-paclitaxel, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Shares Paclitaxel / nab-paclitaxel, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Paclitaxel / nab-paclitaxel, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialGEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Shares Paclitaxel / nab-paclitaxel, Melanoma, Pembrolizumab, Small-cell lung cancer.
- TrialA Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34
Shares Paclitaxel / nab-paclitaxel, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.